At AACR 2026, Revolution Medicines and related programs delivered additional clinical signals for RAS-directed approaches in pancreatic cancer, with updated data spanning monotherapy and combination regimens for daraxonrasib. Separate reporting highlighted strong tumor control outcomes and framed the data as supporting continued development in difficult-to-treat, previously untreated metastatic disease. In parallel, the agenda included other early-phase targeted and ADC programs, reflecting continued interest in molecules designed to address hallmark resistance mechanisms—particularly in pancreatic ductal adenocarcinoma where durable responses remain rare. Revolution’s daraxonrasib program continues to be positioned around stabilizing RAS pathway signaling state rather than relying on mutation-specific covalent binding. For investors and developers, the throughline is clear: RAS remains heavily pursued, and these readouts increase the probability that at least one mechanism can convert historical preclinical promise into consistent clinical benefit.